Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
+0.050 (3.18%)
Oct 28, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Significant capital was raised to advance late-stage programs in PAH and Parkinson’s, with strong investor interest following recent clinical and regulatory milestones. Key trials for both indications are set to progress, with major data readouts and operational expansions expected in the next six months.
-
Enrollment completed for the phase II risvodetinib trial in Parkinson's, with top-line data expected in November. IND filed for IkT-001Pro in PAH, and $4 million raised to extend cash runway into December 2024.